MVR-T7013

**MVR-T7013** is an investigational, genetically engineered oncolytic herpes simplex virus designed by ImmVira for solid tumors as a tumor-targeting enabler for adoptive cell therapy. Within the MVR-T7 platform, MVR-T7013 is described as the construct that drives expression of **CD19** and **HER2** extracellular domains on infected solid tumor cell membranes, with the goal of creating actionable surface antigens for CD19- or HER2-directed cell therapies in tumors that would otherwise lack suitable targets. The vector is also reported to carry **CCL5**, a **PD-1 antibody** transgene, and **IL-12** to promote T-cell infiltration and enhance local antitumor immunity, while retaining the direct tumor-lytic properties of an oncolytic HSV backbone. Publicly available information appears limited to company/industry summaries, and the program appears to have been in **preclinical or IND-enabling development** for **solid tumors** rather than in clearly documented clinical-stage testing specific to MVR-T7013.